197 related articles for article (PubMed ID: 12842123)
1. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade.
Leriche L; Schwartz JC; Sokoloff P
Neuropharmacology; 2003 Aug; 45(2):174-81. PubMed ID: 12842123
[TBL] [Abstract][Full Text] [Related]
2. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice.
Lapin IP; Rogawski MA
Behav Brain Res; 1995 Oct; 70(2):145-51. PubMed ID: 8561905
[TBL] [Abstract][Full Text] [Related]
3. Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice.
Cook CD; Newman JL; Winfree JC; Beardsley PM
Pharmacol Biochem Behav; 2004 Feb; 77(2):309-18. PubMed ID: 14751459
[TBL] [Abstract][Full Text] [Related]
4. Competitive NMDA receptor antagonists do not produce locomotor hyperactivity by a dopamine-dependent mechanism.
Ouagazzal A; Amalric M
Eur J Pharmacol; 1995 Dec; 294(1):137-46. PubMed ID: 8788425
[TBL] [Abstract][Full Text] [Related]
5. Validation and pharmacological characterisation of MK-801-induced locomotor hyperactivity in BALB/C mice as an assay for detection of novel antipsychotics.
Bradford AM; Savage KM; Jones DN; Kalinichev M
Psychopharmacology (Berl); 2010 Oct; 212(2):155-70. PubMed ID: 20676613
[TBL] [Abstract][Full Text] [Related]
6. Dopamine-N-methyl-D-aspartate interactions in the modulation of locomotor activity and memory consolidation in mice.
Mele A; Castellano C; Felici A; Cabib S; Caccia S; Oliverio A
Eur J Pharmacol; 1996 Jul; 308(1):1-12. PubMed ID: 8836626
[TBL] [Abstract][Full Text] [Related]
7. GABAA overactivation potentiates the effects of NMDA blockade during the brain growth spurt in eliciting locomotor hyperactivity in juvenile mice.
Oliveira-Pinto J; Paes-Branco D; Cristina-Rodrigues F; Krahe TE; Manhães AC; Abreu-Villaça Y; Filgueiras CC
Neurotoxicol Teratol; 2015; 50():43-52. PubMed ID: 26056730
[TBL] [Abstract][Full Text] [Related]
8. Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice.
Irifune M; Shimizu T; Nomoto M; Fukuda T
Pharmacol Biochem Behav; 1995; 51(2-3):291-6. PubMed ID: 7667342
[TBL] [Abstract][Full Text] [Related]
9. The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice.
Boulay D; Bergis O; Avenet P; Griebel G
Neuropsychopharmacology; 2010 Jan; 35(2):416-27. PubMed ID: 19759529
[TBL] [Abstract][Full Text] [Related]
10. The 5-HT2A receptor antagonist M100907 is more effective in counteracting NMDA antagonist- than dopamine agonist-induced hyperactivity in mice.
Carlsson ML; Martin P; Nilsson M; Sorensen SM; Carlsson A; Waters S; Waters N
J Neural Transm (Vienna); 1999; 106(2):123-9. PubMed ID: 10226932
[TBL] [Abstract][Full Text] [Related]
11. Differential effects of 7-OH-DPAT and apomorphine on hyperactivity induced by MK-801 (dizocilpine) in rats.
Clements RL; Greenshaw AJ
Neuropharmacology; 2005 Dec; 49(7):1007-16. PubMed ID: 16005475
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Leite JV; Guimarães FS; Moreira FA
Eur J Pharmacol; 2008 Jan; 578(2-3):222-7. PubMed ID: 18021764
[TBL] [Abstract][Full Text] [Related]
13. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists.
Chartoff EH; Heusner CL; Palmiter RD
Neuropsychopharmacology; 2005 Jul; 30(7):1324-33. PubMed ID: 15688082
[TBL] [Abstract][Full Text] [Related]
14. Locomotor activity induced by the non-competitive N-methyl-D-aspartate antagonist, MK-801: role of nucleus accumbens efferent pathways.
De Leonibus E; Mele A; Oliverio A; Pert A
Neuroscience; 2001; 104(1):105-16. PubMed ID: 11311535
[TBL] [Abstract][Full Text] [Related]
15. Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction.
Duncan GE; Moy SS; Lieberman JA; Koller BH
Pharmacol Biochem Behav; 2006 Nov; 85(3):481-91. PubMed ID: 17097724
[TBL] [Abstract][Full Text] [Related]
16. Behavioral evidence for modulation by sigma ligands of (+)MK-801-induced hyperlocomotion in monoamine-depleted mice.
Okuyama S; Imagawa Y; Tomisawa K
Neuropharmacology; 1996 Apr; 35(4):467-74. PubMed ID: 8793909
[TBL] [Abstract][Full Text] [Related]
17. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride.
Martin P; Waters N; Waters S; Carlsson A; Carlsson ML
Eur J Pharmacol; 1997 Sep; 335(2-3):107-16. PubMed ID: 9369362
[TBL] [Abstract][Full Text] [Related]
18. Modulation of the locomotor responses induced by D1-like and D2-like dopamine receptor agonists and D-amphetamine by NMDA and non-NMDA glutamate receptor agonists and antagonists in the core of the rat nucleus accumbens.
David HN; Sissaoui K; Abraini JH
Neuropharmacology; 2004 Feb; 46(2):179-91. PubMed ID: 14680757
[TBL] [Abstract][Full Text] [Related]
19. Effects of NMDA receptor blockers on cocaine-stimulated locomotor activity in mice.
Uzbay IT; Wallis CJ; Lal H; Forster MJ
Behav Brain Res; 2000 Feb; 108(1):57-61. PubMed ID: 10680757
[TBL] [Abstract][Full Text] [Related]
20. Psychotropic drug-induced locomotor hyperactivity and prepulse inhibition regulation in male and female aromatase knockout (ArKO) mice: role of dopamine D1 and D2 receptors and dopamine transporters.
Chavez C; Gogos A; Jones ME; van den Buuse M
Psychopharmacology (Berl); 2009 Oct; 206(2):267-79. PubMed ID: 19597801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
